Odomzo(sonidegib)
Odomzo (sonidegib) is a small molecule pharmaceutical. Sonidegib was first approved as Odomzo on 2015-07-24. It is used to treat skin neoplasms in the USA. It has been approved in Europe to treat basal cell neoplasms. The pharmaceutical is active against protein smoothened.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Odomzo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sonidegib phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ODOMZO | Sun Pharmaceutical Industries | N-205266 RX | 2015-07-24 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| odomzo | New Drug Application | 2023-08-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| skin neoplasms | EFO_0004198 | D012878 | C44 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 4 | 10 | 1 | — | 4 | 18 |
| Basal cell carcinoma | D002280 | — | — | 3 | 10 | 1 | — | 4 | 17 |
| Basal cell neoplasms | D018295 | — | — | 3 | 8 | 1 | — | 4 | 15 |
| Basal cell nevus syndrome | D001478 | EFO_0004136 | — | 1 | 4 | 1 | — | 1 | 6 |
| Syndrome | D013577 | — | — | 1 | 3 | 1 | — | 1 | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 7 | 1 | — | — | 1 | 9 |
| Medulloblastoma | D008527 | — | — | 4 | 3 | — | — | — | 6 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 5 | 1 | — | — | — | 5 |
| Adenocarcinoma | D000230 | — | — | 4 | 1 | — | — | — | 4 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | 2 | — | — | 1 | 4 |
| Leukemia | D007938 | — | C95 | 2 | 1 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 2 | 1 | — | — | — | 2 |
| Essential thrombocythemia | D013920 | — | D47.3 | 2 | 1 | — | — | — | 2 |
| Polycythemia vera | D011087 | — | D45 | 2 | 1 | — | — | — | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 3 | — | — | — | — | 3 |
| Myeloid leukemia | D007951 | — | C92 | 2 | — | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | — | — | — | — | 2 |
| Esophageal neoplasms | D004938 | — | C15 | 2 | — | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | — | — | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | — | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | — | — | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | — | — | — | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | — | — | — | — | 2 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | — | — | — | — | 2 |
Show 41 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sonidegib |
| INN | sonidegib |
| Description | Sonidegib is a member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma. It has a role as an antineoplastic agent, a SMO receptor antagonist and a Hedgehog signaling pathway inhibitor. It is a member of morpholines, an aminopyridine, a member of biphenyls, a member of benzamides, an aromatic ether, an organofluorine compound and a tertiary amino compound. |
| Classification | Small molecule |
| Drug class | hedgehog signaling inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(C(=O)Nc2ccc(N3C[C@H](C)O[C@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 956697-53-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105737 |
| ChEBI ID | — |
| PubChem CID | 24775005 |
| DrugBank | DB09143 |
| UNII ID | 0RLU3VTK5M (ChemIDplus, GSRS) |
Target
Agency Approved
SMO
SMO
Organism
Homo sapiens
Gene name
SMO
Gene synonyms
SMOH
NCBI Gene ID
Protein name
smoothened homolog
Protein synonyms
frizzled family member 11, Protein Gx, seven transmembrane helix receptor, smoothened, frizzled family receptor, smoothened, seven transmembrane spanning receptor
Uniprot ID
Mouse ortholog
Smo (319757)
smoothened homolog (P56726)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,058 documents
View more details
Safety
Black-box Warning
Black-box warning for: Odomzo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
768 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use